Onco Actu du 25 juin 2019

	3.1.1 PRÉVENTION - TABAC - E-CIGS
The debate over e-cigarettes demands stronger evidence of their value [Nature] Whether the devices help people to quit, or increase health risks, will emerge only from better data.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
Interim Scan during Prostate Cancer Therapy Helps Guide Treatment [SNMMI] Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival.
Nuclear Medicine PSMA-Targeted Study Offers New Options for Cancer Theranostics Worldwide [SNMMI] “Similar to hybrid cars that are driven by either a combustion engine or an electric engine (one is switched on, while the other is switched off), we have designed for the very first time radiopharmaceuticals with two ‘nuclear engines’ or isotopes,” explains Alexander Wurzer at Technical University Munich in Garching, Germany.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
As Million European Genomes Initiative Advances, Alliance Promotes New Personalized Medicine Project [Genome Web] The initiative, initially referred to as MEGA, which has pledged to make a million genomes accessible to researchers by 2022,is a step toward developing the infrastructure to support genomic data sharing across Europe. However, other projects are necessary to realize personalized medicine in Europe, according to Denis Horgan, executive director of the European Alliance for Personalized Medicine.
	4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
‘I can change it for others’: the woman who exposed Irish smear tests scandal [The Guardian] If a test in 2011 had been accurate, Vicky Phelan might have avoided cancer. Now she is trying to give some hope to terminal patients.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Infrared imaging technology being developed to better detect breast cancer [Rochester Institute of Technology] Thermography studies have been done in the past, but the technology today is more sensitive and it is through these advancements that the RIT team has been able to show far more detail in images and validate tumor locations. The infrared test takes 20 minutes compared to an MRI which may take up to 45 minutes.
The popularity of 3D mammograms is taking off, but not in every part of the US, study says [CNN] 3D mammograms haven't yet been proven to be the best screening tool for breast cancer, but more women in the United States are getting them.
More women in U.S. receive 3-D mammography but disparities remain [Yale University] “Although there is a lot of interest in this new technology, we don’t know much about how it will affect the long-term health of women,” Richman noted. “There are ongoing studies designed to answer these questions, and we hope to have clearer answers in the next few years.”
	5. TRAITEMENTS
Which Neoadjuvant Treatment Strategy for High-Risk Resectable Melanoma? [ESMO] NeoCombi and OpACIN-neo point to a critical assessment of patterns of relapse to two neoadjuvant treatment approaches.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Hope for aggressive breast cancers as diabetes drug creates new potential avenue for treatment [Breast Cancer Now] Researchers used diabetes drug metformin to treat breast cancer stem cells, which are thought to be involved in the spread of breast cancer around the body. In experiments done in the lab, low-dose metformin treatment led to a shift in the way these cells make energy, opening up new ways to target aggressive forms of the disease.
	5.10 TRAITEMENTS - ESSAIS
FDA lifts hold on AbbVie, Roche's Venclexta in myeloma after drugmakers pledge risk remedies [Fierce Pharma] The FDA’s limited decision follows a troubled three months for the med after a series of deaths in a Venclexta phase 3 multiple myeloma trial, called Bellini 3, halted new enrollment and threatened to end the program altogether.
FDA lifts hold on AbbVie multiple myeloma study [Biopharma Dive] That regulatory action has slowed Venclexta's progress in multiple myeloma, but resuming the CANOVA trial could help AbbVie get back on track. Venclexta is also in clinical testing for non-Hodgkin's lymphoma and myelodysplastic syndrome.
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality [AbbVie] All other clinical trials evaluating venetoclax in patients with multiple myeloma remain on partial clinical hold while next steps continue to be evaluated with the agency. The partial clinical hold does not impact any of the approved indications for venetoclax, such as chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML).
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud [EndPoints] The rest of the myeloma studies, though, will continue without new patients for now as the FDA sorts out why researchers spotted an imbalance in the death rate between the drug arm and the control group — venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
How inhibiting both HDAC and PD-1 could improve immuno-oncology treatments [Fierce Biotech] Could combining HDAC and PD-1 inhibitors be the answer to improving responses to both? Startup OnKure Therapeutics, which has an HDAC inhibitor in a phase 1 trial, and collaborators at the University of Colorado Cancer Center have early evidence in mice that the approach might work.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Bristol-Myers Squibb’s Opdivo misses its shot at earlier use in liver cancer [Fierce Pharma] Opdivo has been grabbing share in that indication, and Merck’s rival immunotherapy Ketyruda, which bears its own green light in the setting, just failed to confirm its own approval by showing it couldn't fend off tumor progression or prolong patients’ lives.
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma [BMS] While CheckMate -459 did not reach its pre-specified primary endpoint, the results showed a clear trend towards improvement in OS for patients treated with Opdivo compared to sorafenib, a current standard of care.
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market [EndPoints] The OS rate on Opdivo fell well short of statistical significance, with a p value of 0.0752. We’ll have to wait for an upcoming science conference to get the full picture.
	5.17 TRAITEMENTS - RADIOTHÉRAPIE
Wearable Technology to Personalize Lu-177-DOTATATE Therapy for NETs [SNMMI] Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin-receptor-2 positive neuroendocrine tumors (NETs).
	5.2 PHARMA
GSK wins speedy FDA Zejula review in ovarian cancer niche [Fierce Pharma] The application is based on data in a trial called Quadra that found “clinically relevant activity” for the patients when treated with the drug. Investigators noted that the patients have few options, and that survival after the third line of treatment ranges from 5 months to 9 months.
U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review [GSK] The application was granted priority review and has an action date of 24 October 2019.
	6.1 OBSERVATION
Survivors of Childhood Brain Tumors Experience Lasting Cognitive and Socioeconomic Burdens [Wiley] To assess such burdens, M. Douglas Ris, PhD, of Baylor College of Medicine and Texas Children’s Hospital, and his colleagues at St. Jude Children’s Research Hospital, compared 181 survivors of pediatric low-grade glioma with 105 siblings of cancer survivors who were participating in the Childhood Cancer Survivor Study.
	6.7 DMP, BIG DATA & APPLIS
PatientsLikeMe, forced by U.S. to ditch Chinese investor, sold to UnitedHealth Group [STAT] PatientsLikeMe was founded in 2004. It pairs a social network, where patients connect with other people with the same condition using technology that makes it easier for patients to track and share their symptoms and for the company to do research on diseases.